Form 8-K - Current report:
SEC Accession No. 0001193125-24-164461
Filing Date
2024-06-20
Accepted
2024-06-20 16:16:55
Documents
15
Period of Report
2024-06-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d857947d8k.htm   iXBRL 8-K 38756
2 EX-10.1 d857947dex101.htm EX-10.1 192333
6 GRAPHIC g857947g0620161501854.jpg GRAPHIC 2767
  Complete submission text file 0001193125-24-164461.txt   401047

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20240617.xsd EX-101.SCH 2889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20240617_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20240617_pre.xml EX-101.PRE 11287
19 EXTRACTED XBRL INSTANCE DOCUMENT d857947d8k_htm.xml XML 3669
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 241056449
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)